VeriStrat (R) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528

O. Gautschi, A.M. Dingemans, S. Crowe, S. Peters, H. Roder, J. Grigorieva, J. Roder, F. Zappa, M. Pless, M. Brutsche, F. Baty, L. Bubendorf, S.F.H. Schmitz, K.J. Na, D. Carbone, R. Stahel, E. Smit

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)59-64
JournalLung Cancer
Volume79
Issue number1
DOIs
Publication statusPublished - 2013

Cite this